With Christian Gnam, the IZB a new management with management experience and a large international network. Most recently, Gnam was Managing Director at Insurtech Hub Munich (ITHM) There, he significantly drove the hub's growth, accelerated collaboration between startups, tech companies, and insurance companies, and continuously developed ITHM. Previously, Gnam headed the investment team for startups, life sciences, energy and environmental technology, and chemicals at Invest in Bavaria. From 2010 to 2012, Gnam worked for the City of Munich at Referat für Arbeit und Wirtschaft, focusing on expanding economic relations with China. At the beginning of his professional career, he worked in business development for various industries in São Paulo, Brazil. Gnam studied economic geography, economics, and political science at Ludwig Maximilian University in Munich, with a particular focus on foreign trade, market entry, and location development.
Gnam takes over management of Zobel
Peter Zobel has been the managing director of the IZB since its founding in 1995 and has developed the location into an important Biotechnology Center in Europe. The outgoing Managing Director sable explained:
"My daily commitment to the IZB and our founders has given me great joy over the past 28 years. Now, I am handing over the IZB, fully leased to excellent startups and with a fantastic team of employees, to my successor. I wish the IZB continued prosperity under its new management and continued support of the courageous entrepreneurs at the startups, thereby contributing to their success. I hope that politicians will be motivated to further strengthen the IZB in the coming years."
And Gnam added:
"I am delighted to take on this role, especially given my enthusiasm for new technologies and the promotion of innovation. Biotechnology is a future-oriented industry that, in its numerous fields of application, aims to significantly improve people's lives. The Munich metropolitan region, with its many pharmaceutical companies, cutting-edge research institutes, and broad industrial and technological mix, already offers good conditions for biotechnology growth. We must further leverage this potential and continuously invest in the industry to remain among the top life science locations worldwide."
